NEW
YORK, July 20, 2022 /PRNewswire/ -- Sadis
& Goldberg has been retained by stockholders of Meihua
International Medical Technologies Co., Ltd. (NASDAQ: Ticker
"MHUA") to investigate alleged accounting fraud by
MHUA and/or its officers and directors. Our investigation focuses
on MHUA's violation of NASDAQ Rules by failing to timely file its
Annual Report containing its financial statements. Shortly
thereafter, MHUA's independent Auditor resigned, as did the
Chairman of MHUA's Audit Committee. As a result, MHUA's stock price
has fallen from as high as $14.80 per
share to $5.30.
Our investigation focuses on a violation of
NASDAQ Rules by failing to timely file its Annual Report.
These developments raise major concern that MHUA's current and
prior financial statements are false and misleading. Further, they
raise serious concerns that MHUA, its officers and/or directors may
have presented false and misleading financial information in the
Prospectus for MHUA's Initial Public (IPO) in February 2022.
Sadis & Goldberg is investigating potential direct and
derivative claims that MHUA and its officers and directors breached
their fiduciary duties, engaged in common law fraud, and/or
violated securities laws through false accounting and financial
statements.
If you are an investor in MHUA, and wish to obtain additional
information to protect your investment or recover losses, please
contact Samuel J. Lieberman of Sadis
& Goldberg at (212) 573-8164 or by email at
SLieberman@sglawyers.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sadis--goldberg-retained-to-investigate-allegations-of-accounting-fraud-at-meihua-international-medical-technologies-co-ltd-mhua-301590078.html
SOURCE Sadis & Goldberg LLP